Search results for: Pricing and Reimbursement
Filter search results
The broader economic benefits of COVID-19 vaccination
13 October 2025
…working and productive. Continued investment in comprehensive vaccination policies and COVID-19 vaccines is essential to reduce its ongoing and future burden. Extending COVID-19 vaccination eligibility to working-age adults could nearly…
New OHE model estimates COVID-19 could be associated with costs of £7 billion a year in the UK, without annual autumn vaccinations
13 October 2025
…and life sciences, we partner with Universities, Government, health systems and the pharmaceutical industry to research and respond to global health challenges. As a government–recognised Independent Research Organisation and…
Real-World Evidence: Current Best Practice for Reimbursement Decision-Making
15 May 2023
…decisions. We discuss the next steps for enhancing the assessment and use of quality RWE in reimbursement decisions. RECOMMENDATIONS Several guidelines and frameworks have been produced and are welcomed, with…
Fishing for Innovative Drugs with the ODRS: Potential Benefits and Challenges
6 February 2023
…the beginning of his acceptance speech, Professor Hollis invited us to consider innovative drug pricing and reimbursement with a fishing analogy. There are multiple strategies for catching fish, for example,…
From STEDI to STRIDES: Valuing broader health-system benefits of AMR diagnostics
21 July 2025
…economies worldwide. To this end, key priorities include prevention and infectious disease management, increasing uptake and access to treatment and diagnoses and overall improved antimicrobial stewardship. The evolving understanding of…
Advancing Rare Disease Care: Challenges and Key Issues
28 February 2025
…and pricing and reimbursement—to support a resilient healthcare and innovation ecosystem for rare diseases. Promoting equitable access to medicines for rare diseases is a key component of the World Health…
OHE Involved in Developing New AMS Report on Stratified Medicines
15 July 2013
…personalised medicine. The pricing and reimbursement recommendations included in the report include the following. Introducing flexible pricing for drugs and prices reflective of value for diagnostics. This is to address…
Our Contributions to the Economics of Personalised Medicine
7 March 2018
…pricing and market access agreements This strand of research considers various pricing strategies to incentivise the R&D of personalised medicines and increase their uptake. This includes incentivising combination therapies…
MoCA Initiative and its Value Framework: An Opportunity to Improve Decision Making for Orphan Drugs in Europe?
18 September 2018
…to all parties involved and how it can improve decision making for – and access to – orphan drugs in European countries. There is considerable variation in the degree and…